| Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds | 09/18 08:30 | globenewswire.com |
| Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership | 08/14 08:30 | globenewswire.com |
| Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease | 06/06 08:30 | globenewswire.com |
| Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update | 05/15 18:00 | globenewswire.com |
| Vaccinex Reports 2023 Financial Results and Provides Corporate Update | 04/02 08:30 | globenewswire.com |
| Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules | 03/27 08:30 | globenewswire.com |
| Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology | 02/21 08:00 | globenewswire.com |
| Vaccinex, Inc. Announces Reverse Stock Split | 02/15 08:00 | globenewswire.com |
| Vaccinex Announces Pricing of $3.7 Million PIPE Financing | 02/07 08:00 | globenewswire.com |
| Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule | 12/04 08:00 | globenewswire.com |